Please enable JavaScript.
Coggle requires JavaScript to display documents.
HER2+ BC - Coggle Diagram
HER2+ BC
adjuvant therapy
-
-
-
APT
-
-
90% patients had tumor <2 cm
-
APHINITY
After surgery and central HER2-positive confirmation, 4,805 patients with node-positive or high-risk node-negative BC were randomly assigned (1:1) to either 1-year pertuzumab or placebo added to standard adjuvant chemotherapy and 1-year trastuzumab.
PERJETA is beneficial only in nodal + disease
Node-positive cohort: HR 0.72 [95% CI, 0.59 to 0.87]), 6-year IDFS 88 vs 83%. Benefit was not seen in the node-negative cohort. In a subset analysis HR 0.73 (95% CI, 0.59 to 0.92) for HR+ disease and aHR 0.83 (95% CI, 0.63 to 1.10) for HR-disease. Primary cardiac events remain < 1% in both the treatment groups.
-
-
-
-